4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 53 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $5,181,000 | – | 125,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 378,288 | $16,410,000 | 6.18% |
| Aquilo Capital Management, LLC | 300,886 | $13,052,000 | 2.36% |
| BVF INC/IL | 1,031,070 | $44,728,000 | 1.68% |
| Casdin Capital, LLC | 995,354 | $43,178,000 | 1.29% |
| Ally Bridge Group (NY) LLC | 150,000 | $6,507,000 | 1.25% |
| Eagle Health Investments LP | 50,000 | $2,169,000 | 0.85% |
| Soleus Capital Management, L.P. | 86,100 | $3,735,000 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $170,827,000 | 0.51% |
| ArrowMark Colorado Holdings LLC | 1,048,189 | $45,471,000 | 0.34% |
| ACUTA CAPITAL PARTNERS, LLC | 20,000 | $868,000 | 0.31% |